{"id":"https://openalex.org/W7225345271","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0514","title":"514 Initial clinical results from START-002: a phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR + /HER2 - mBC","display_name":"514 Initial clinical results from START-002: a phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triple-negative or HR + /HER2 - mBC","publication_year":2026,"publication_date":"2026-11-01","ids":{"openalex":"https://openalex.org/W7225345271","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0514"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2026-sitc2026.0514","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0514","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0514","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A575.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/14/Suppl_2/A575.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057580348","display_name":"Steven Jay Isakoff","orcid":"https://orcid.org/0000-0002-6677-1014","observed_orcids":["https://orcid.org/0000-0002-6677-1014"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven J Isakoff","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108293870","display_name":"Anastasia Martynova","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210117038","display_name":"USC Norris Comprehensive Cancer Center","ror":"https://ror.org/01nmyfr60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800154431","https://openalex.org/I4210117038"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anastasia Martynova","raw_affiliation_strings":["USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I4210117038"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022515427","display_name":"Margaret Elena Gatti-Mays","orcid":"https://orcid.org/0000-0001-8914-2897","observed_orcids":["https://orcid.org/0000-0001-8914-2897"]},"institutions":[{"id":"https://openalex.org/I2799885155","display_name":"The Ohio State University Comprehensive Cancer Center \u2013 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute","ror":"https://ror.org/028t46f04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799885155","https://openalex.org/I2802841970"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Margaret E Gatti-Mays","raw_affiliation_strings":["The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA","institution_ids":["https://openalex.org/I2799885155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078027841","display_name":"Nathalie LeVasseur","orcid":"https://orcid.org/0000-0002-2581-4903","observed_orcids":["https://orcid.org/0000-0002-2581-4903"]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Nathalie LeVasseur","raw_affiliation_strings":["BC Cancer Vancouver Centre, Vancouver, BC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BC Cancer Vancouver Centre, Vancouver, BC, Canada","institution_ids":["https://openalex.org/I1289530486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5138682735","display_name":"Philippe L. Bedard","orcid":"https://orcid.org/0000-0002-6771-2999","observed_orcids":["https://orcid.org/0000-0002-6771-2999"]},"institutions":[{"id":"https://openalex.org/I2802654988","display_name":"Princess Margaret Cancer Centre","ror":"https://ror.org/03zayce58","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1325899441","https://openalex.org/I2802654988"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Philippe L Bedard","raw_affiliation_strings":["Princess Margaret Hospital Cancer Centre, Toronto, ON, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Princess Margaret Hospital Cancer Centre, Toronto, ON, Canada","institution_ids":["https://openalex.org/I2802654988"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059305054","display_name":"Rena Desai Callahan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2799798094","display_name":"UCLA Health","ror":"https://ror.org/01d88se56","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094"]},{"id":"https://openalex.org/I4390039293","display_name":"UCLA Jonsson Comprehensive Cancer Center","ror":"https://ror.org/0599cs764","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rena Callahan","raw_affiliation_strings":["UCLA Health Jonsson Cancer Center, Los Angeles, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA Health Jonsson Cancer Center, Los Angeles, CA, USA","institution_ids":["https://openalex.org/I2799798094","https://openalex.org/I4390039293"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063863618","display_name":"Jessica Trevi\u00f1o Jones","orcid":"https://orcid.org/0009-0004-2454-4480","observed_orcids":["https://orcid.org/0009-0004-2454-4480"]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Trevino Jones","raw_affiliation_strings":["UT Health San Antonio, San Antonio, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT Health San Antonio, San Antonio, TX, USA","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160984867","display_name":"Andreas J Varkaris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andreas J Varkaris","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA, USA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091886381","display_name":"William Randolph","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"William Randolph","raw_affiliation_strings":["Marengo Therapeutics, Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marengo Therapeutics, Inc, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065179224","display_name":"Karunya Srinivasan","orcid":"https://orcid.org/0009-0009-8644-5847","observed_orcids":["https://orcid.org/0009-0009-8644-5847"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karunya Srinivasan","raw_affiliation_strings":["Marengo Therapeutics, Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marengo Therapeutics, Inc, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062487589","display_name":"Shannon McCue","orcid":"https://orcid.org/0009-0004-0950-5352","observed_orcids":["https://orcid.org/0009-0004-0950-5352"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shannon McCue","raw_affiliation_strings":["Marengo Therapeutics, Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marengo Therapeutics, Inc, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113735251","display_name":"Zhenming Shun","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhenming Shun","raw_affiliation_strings":["Marengo Therapeutics, Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marengo Therapeutics, Inc, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160935879","display_name":"Ke Liu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ke Liu","raw_affiliation_strings":["Marengo Therapeutics, Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marengo Therapeutics, Inc, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160983046","display_name":"Zhen Su","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhen Su","raw_affiliation_strings":["Marengo Therapeutics, Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marengo Therapeutics, Inc, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050974773","display_name":"Kevin M. Chin","orcid":"https://orcid.org/0000-0002-5062-4159","observed_orcids":["https://orcid.org/0000-0002-5062-4159"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin Chin","raw_affiliation_strings":["Marengo Therapeutics, Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Marengo Therapeutics, Inc, Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047918797","display_name":"Virginia Kaklamani","orcid":"https://orcid.org/0000-0002-3313-8458","observed_orcids":["https://orcid.org/0000-0002-3313-8458"]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Virginia Kaklamani","raw_affiliation_strings":["UT Health San Antonio, San Antonio, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT Health San Antonio, San Antonio, TX, USA","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5156929689","display_name":"Erika Hamilton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erika Hamilton","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN, USA","institution_ids":["https://openalex.org/I4210100810"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":9,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A575","last_page":"A575"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8213000297546387,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8213000297546387,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.09749999642372131,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.029500000178813934,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sacituzumab-govitecan","display_name":"sacituzumab govitecan","score":0.9750000238418579},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.8489999771118164},{"id":"https://openalex.org/keywords/hr-her2-breast-cancer","display_name":"hormone receptor-positive HER2-negative breast cancer","score":0.8709999918937683},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9490000009536743},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.7350000143051147},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.5910000205039978},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.593999981880188}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8252000212669373},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.474700003862381},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4480000138282776},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4235999882221222},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4050000011920929},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.40369999408721924},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.36169999837875366},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.3488999903202057},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.28450000286102295},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.26570001244544983}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1136/jitc-2026-sitc2026.0514","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0514","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0514","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A575.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},{"id":"pmh:oai:doaj.org/article:0e04ad1237c549db9692cfe26b41f50d","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/0e04ad1237c549db9692cfe26b41f50d","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal for ImmunoTherapy of Cancer, Vol 14, Iss Suppl 2 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2026-sitc2026.0514","doi":"https://doi.org/10.1136/jitc-2026-sitc2026.0514","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2026-sitc2026.0514","pdf_url":"https://jitc.bmj.com/content/14/Suppl_2/A575.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225345271.pdf","grobid_xml":"https://content.openalex.org/works/W7225345271.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7154723411","https://openalex.org/W7129367339","https://openalex.org/W7129514054","https://openalex.org/W4415871394","https://openalex.org/W4416391673","https://openalex.org/W7223340075","https://openalex.org/W4412479874","https://openalex.org/W4409821756","https://openalex.org/W4404067387","https://openalex.org/W4410810027"],"abstract_inverted_index":{"Background":[0],"Invikafusp":[1],"alfa":[2],"(invika),":[3],"a":[4,28,68,199,205,210,223],"first-in-class":[5],"dual":[6],"T-cell":[7],"agonist,":[8],"has":[9,187],"demonstrated":[10],"monotherapy":[11,339],"clinical":[12,176,363,377,397],"responses":[13,150,161,374],"across":[14],"multiple":[15],"TMB-H":[16],"solid":[17],"tumor":[18,155],"types":[19],"including":[20,198,371],"triple-negative":[21],"breast":[22,212],"cancer":[23],"(TNBC).":[24],"Sacituzumab":[25],"govitecan":[26],"(SG),":[27],"TROP-2\u2013directed":[29],"antibody\u2013drug":[30],"conjugate":[31],"(ADC),":[32],"is":[33,67,124,145,172],"approved":[34],"for":[35],"mTNBC":[36,80,133,136,202,217,231],"and":[37,56,101,130,215,232,283,300,321,333,375,382],"HR":[38,83,127,383],"+/HER2-":[39,84,128,384],"mBC.":[40,85],"START-002":[41,66],"evaluates":[42],"the":[43,47,122,143,237,247,349],"hypothesis":[44],"that":[45],"combining":[46],"immunomodulatory":[48],"potential":[49],"of":[50,58,209,222,240,250,351,365,399],"SG":[51,77,243,263],"with":[52,76,138,158,175,192,201,219,246,262,295,369,386],"invika-mediated":[53],"selective":[54,334],"activation":[55],"expansion":[57,107,336],"tumor-reactive":[59],"V\u03b26/V\u03b210":[60],"T-cells":[61],"will":[62],"enhance":[63],"anti-tumor":[64],"activity.Methods":[65],"Ph":[69,95],"1b/2":[70],"study":[71,359],"evaluating":[72],"invika":[73,241,296,340,366],"in":[74,78,126,132,153,181,190,330,367,379,389],"combination":[75,238,368],"2L+":[79],"or":[81,195],"3L+":[82],"Patients":[86],"may":[87],"have":[88],"received":[89],"prior":[90,116,120],"CPI":[91],"and/or":[92],"ADC.":[93],"The":[94,168,253,290],"1b":[96],"safety":[97,102,239,388],"run-in":[98],"evaluated":[99],"feasibility":[100],"followed":[103],"by":[104],"separate":[105],"Ph2":[106],"cohorts.Results":[108],"Among":[109],"22":[110],"evaluable":[111],"heavily":[112,390],"pre-treated":[113,391],"(median":[114],"4":[115],"lines)":[117],"patients":[118,137,191,229],"without":[119],"SG,":[121,370],"ORR":[123,144],"33%":[125],"(4/12)":[129],"30%":[131],"(3/10).":[134],"In":[135],"PD-L1":[139],"CPS":[140],"<":[141],"10,":[142],"60%":[146],"(3/5).":[147],"Confirmed":[148],"complete":[149,207,220,373],"were":[151,297,341],"observed":[152,189],"both":[154,380],"subtypes,":[156],"along":[157],"5":[159],"partial":[160],"(3":[162],"HR+/HER2-,":[163],"2":[164],"TNBC)":[165],"(figure":[166],"1).":[167],"disease":[169],"control":[170],"rate":[171],"82%":[173],"(18/22),":[174],"benefit":[177,378],"persisting":[178],">24":[179],"weeks":[180],"6":[182],"patients.":[183,392],"Notably,":[184],"antitumor":[185],"activity":[186,364],"been":[188],"chest":[193,225],"wall":[194,226],"skin":[196,213],"disease,":[197,385],"patient":[200,218],"who":[203],"achieved":[204],"durable":[206,376],"response":[208,352,411],"10-cm":[211],"lesion,":[214],"another":[216],"resolution":[221],"3-cm":[224],"lesion.Among":[227],"41":[228],"(18":[230],"23":[233],"HR+/HER2-":[234],"mBC)":[235],"treated,":[236],"+":[242],"was":[244],"consistent":[245],"known":[248],"toxicities":[249],"each":[251],"agent.":[252],"most":[254,291],"common":[255,292],"treatment":[256],"related":[257],"adverse":[258],"events":[259],"(TRAE)":[260],"associated":[261,294],"included:":[264,301],"diarrhea":[265],"(44%":[266],"grade":[267,299,309],"1-2,":[268,274,280,287,307,317,325],"20%":[269],"gr3-4),":[270,276,282],"neutropenia":[271],"(5%":[272],"gr":[273,279,286,306,312,316,319,324,327],"54%":[275],"fatigue":[277,322],"(41%":[278],"12%":[281,326],"nausea":[284],"(37%":[285],"5%":[288],"gr3-4).":[289],"TRAEs":[293],"low":[298],"cytokine":[302],"release":[303],"syndrome":[304],"(68%":[305],"7%":[308,318],"3,":[310],"no":[311],"4),":[313],"rash":[314],"(34%":[315],"3-4),":[320],"(22%":[323],"3-4).Dose-dependent":[328],"increases":[329],"Cmax/":[331],"AUC":[332],"TRBV6":[335],"similar":[337],"to":[338,346],"observed.":[342],"Additional":[343],"translational":[344],"analyses":[345],"further":[347],"understand":[348],"mechanisms":[350],"are":[353],"currently":[354],"being":[355],"performed.Conclusions":[356],"This":[357],"first-in-human":[358],"demonstrates":[360],"encouraging":[361],"preliminary":[362],"confirmed":[372],"TNBC":[381],"manageable":[387],"These":[393],"data":[394],"support":[395],"continued":[396],"development":[398],"this":[400],"novel":[401],"combination.Abstract":[402],"514":[403],"Figure":[404],"1":[405],"Waterfall":[406],"plot:":[407],"best":[408],"target":[409],"lesion":[410]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-11-06T00:00:00"}